| Name | Title | Contact Details |
|---|
Glympse Bio is developing a powerful new paradigm in diagnostics to enable noninvasive and predictive monitoring of multiple human diseases.
Immunomedics is a leader in next-generation antibody-drug conjugate (ADC) technology, committed to help transform the lives of people with hard-to-treat cancers.
Aldeyra Therapeutics, Inc., is a biotechnology company focused primarily on the development of products to treat diseases thought to be related to endogenous free aldehydes, a naturally occurring class of toxic molecules. The company has developed NS2, a product candidate designed to trap free aldehydes. Aldeyra plans to begin clinical testing of NS2 in 2014 for the treatment of Sjögren-Larsson Syndrome and acute anterior uveitis. NS2 has not been approved for sale in the U.S. or elsewhere.
TARA pioneers predictive tissue models that enable faster, safer, and more reliable development of new medicines. Treatments can make it to market more rapidly, enabling better health and longer life for people.
Enzon Pharmaceuticals Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.